Please assess the completion status of the following clinical trial:

Trial Title: ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Current diagnosis of alcohol dependence, meeting at least 3 criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV)~* Recently completed alcohol detoxification and seeking treatment for alcohol dependence~* Women of childbearing potential must agree to use an approved method of contraception for study duration~Primary Exclusion Criteria:~* Pregnancy or lactation~* Evidence of hepatic failure including: ascites, bilirubin \>10% above upper limit of normal (ULN) and/or esophageal variceal disease~* Current dependence (within the past year) to benzodiazepines or cocaine, or current or history of opioid dependence according to DSM-IV criteria~* Use of any opioids and/or methadone within 14 days prior to the screening visit, or likely to require opioid therapy during the study period~* Previous enrollment in a VIVITROL clinical trial or previous VIVITROL experience~* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)~* Parole, probation, or pending legal proceedings having the potential for incarceration during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VIVITROL 380 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).